Some biopharmas are beginning to view the tumultuous public markets with a wary eye. Infectious disease specialist Viamet Pharmaceuticals Holdings LLC, which filed in July for a $75 million initial public offering (IPO), is looking through the rearview mirror after filing Monday to withdraw its registration statement.